What is the vaginal contraceptive ring?

The vaginal contraceptive ring is a reversible hormonal method of birth control delivered by a flexible polymer ring placed inside the vagina. First approved for widespread use in the early 2000s, contemporary ring products provide cyclic contraception via continual local release of a combined estrogen–progestin formulation (or a progestin/estrogen combination in newer systems). The ring is available by prescription and is an option for people across reproductive ages who want effective, user-controlled contraception without daily dosing (Mayo Clinic; Cleveland Clinic).

Commonly available ring products include etonogestrel/ethinyl estradiol rings (e.g., NuvaRing) designed for single-cycle monthly use, and a reusable ring (Annovera) that delivers segesterone acetate plus ethinyl estradiol and is intended for repeated use over 13 cycles (one year) (Mayo Clinic; FDA information).

Sources: Mayo Clinic; Cleveland Clinic; U.S. Food and Drug Administration (manufacturer product information).

How the contraceptive ring works

The ring delivers low, steady doses of hormones directly to the vaginal mucosa. The hormones act primarily by:

Suppressing ovulation (preventing release of an egg from the ovaries).
Thickening cervical mucus to reduce sperm penetration.
Altering the endometrial lining to make implantation less likely.

Because the hormones are released locally, systemic exposure is generally lower than with some oral contraceptives, though plasma hormone levels are sufficient to suppress ovulation and provide effective contraception (Mayo Clinic; ACOG). The mechanism of action is the same principal mechanism used by combined oral contraceptive pills: combined estrogen and progestin work synergistically to prevent ovulation and to create multiple changes that reduce the chance of fertilization and implantation.

Source: American College of Obstetricians and Gynecologists (ACOG); Mayo Clinic.

Types of vaginal rings and dosing schedules

NuvaRing (etonogestrel/ethinyl estradiol): A single-use flexible ring inserted vaginally for 21 consecutive days and removed for a 7‑day ring‑free interval during which withdrawal bleeding typically occurs. A new ring is inserted after the 7‑day ring‑free interval (Mayo Clinic).

Annovera (segesterone acetate/ethinyl estradiol): A reusable ring supplied in a case; the same ring is inserted for 21 days, removed for 7 days each cycle, and reinserted for a total of 13 cycles (1 year). The ring is stored in its case during the 7-day interval between cycles (FDA; manufacturer instructions).

Different products have distinct labeling, and patients should follow the specific instructions for the ring they are prescribed (FDA; product labeling).

Source: Mayo Clinic; FDA (Annovera product information).

Who is a candidate? Contraindications and medical eligibility

The vaginal ring is a combined hormonal contraceptive and is subject to the same general medical eligibility considerations as combined oral contraceptives and the contraceptive patch. Most healthy, nonpregnant people who do not have specific contraindications are eligible. Contraindications include, but are not limited to (ACOG; CDC Medical Eligibility Criteria):

Current or history of venous thromboembolism (deep vein thrombosis or pulmonary embolism).
Known thrombogenic mutations (e.g., antiphospholipid syndrome) in some circumstances.
Current or past ischemic heart disease, stroke, or transient ischemic attack.
Uncontrolled hypertension (blood pressure typically >160/100 mm Hg).
Migraine with aura (increased cerebrovascular risk with estrogen-containing methods).
Active liver disease or liver tumors.
Known or suspected breast cancer or other estrogen- or progestin-sensitive cancers.
Smoking and age 35 years or older (combined hormonal products carry higher thrombotic risk in this group).

The U.S. Centers for Disease Control and Prevention (CDC) publishes the U.S. Medical Eligibility Criteria (MEC) for contraceptive use, which provides detailed clinical guidance on who can safely use combined hormonal contraception, including vaginal rings (CDC).

Source: ACOG; CDC U.S. Medical Eligibility Criteria for Contraceptive Use.

Effectiveness

When used perfectly (inserting and removing according to the prescribed schedule), combined hormonal rings are highly effective at preventing pregnancy. Typical-use efficacy is somewhat lower than perfect-use efficacy because of user errors such as delayed insertion, ring expulsion, or prolonged ring-free intervals.

Typical-use pregnancy rates for combined rings are similar to those reported for combined oral contraceptives and are estimated in the range of 2–9 pregnancies per 100 woman‑years depending on study and population; perfect-use rates are lower (Mayo Clinic; clinical trials data). Real-world effectiveness depends on correct and consistent use and adherence to timing rules after insertion or expulsion.

Source: Mayo Clinic; clinical trial and product labeling summaries.

How to use the vaginal ring — insertion, removal, and schedules

General principles (follow the specific product instructions provided by your prescriber and the product labeling):

Insertion technique: Wash hands. Squeeze the flexible ring together and gently insert it into the vagina. The ring can be positioned high or low in the vaginal canal; exact placement is not critical as long as it is comfortable. You should not feel the ring during normal activities. There is no requirement to remove the ring before hygienic practices such as bathing (Mayo Clinic; Cleveland Clinic).

Removal technique: Hook a finger under the ring and gently pull it out. Dispose of single-use rings as instructed (for example, wrap and discard in household trash). Reusable rings (Annovera) are stored in their case during the 7-day removal interval and kept according to manufacturer guidance.

Routine schedule:
Typical cyclic regimen: Insert for 21 consecutive days, remove for 7 days (ring‑free interval). During the ring‑free week, withdrawal bleeding usually occurs. Insert a new ring after the 7‑day interval.
Start options: “Day 1” start (insert on the first day of menses so no backup contraception is needed), Sunday start (insert on the first Sunday after menstruation begins; backup for 7 days may be recommended), or “quick start” (insert at any point after confirming not pregnant; use backup contraception for 7 days). Specific instructions and need for backup contraception depend on where the start occurs in the menstrual cycle and whether there was prior contraceptive use. If starting after first‑trimester pregnancy or extended use of another method, follow provider guidance (Mayo Clinic; product labeling).

What to do if you forget to insert a new ring after the ring‑free week: If you are within the timeframe specified in the product labeling (usually within 7 days), reinsert the ring as soon as possible and use backup contraception (e.g., condoms) for 7 days. If in doubt, contact a clinician or follow the product instructions; emergency contraception may be considered if there was unprotected intercourse during a lapse (Mayo Clinic; product labeling).

Sources: Mayo Clinic; product labeling; Cleveland Clinic.

Handling expulsion or prolonged ring removal

Occasional ring expulsion can occur (for example, during tampon removal, bowel movements, or other activities). Management depends on how long the ring has been out:

If the ring has been out for less than 3 hours: Rinse the ring with lukewarm water (do not use soaps, medications, or disinfectants) and reinsert it. No additional contraceptive protection is usually required if this occurs during weeks 1 or 2 of the cycle (manufacturer guidance; Mayo Clinic).

If the ring has been out for more than 3 hours during weeks 1 or 2: Rinse and reinsert, and use backup contraception (e.g., condoms or abstain) for 7 days. Consider emergency contraception if unprotected intercourse occurred during the lapse.

If the ring has been out for more than 3 hours during week 3, or if you are unsure how long it has been out: Follow the specific product instructions, which may include discarding the ring and starting a new ring immediately or completing a ring‑free interval and starting a new ring. Use backup contraception for 7 days or consider emergency contraception as indicated (product labeling; CDC guidance).

Always consult the specific product’s patient information and contact a clinician for individualized instructions; guidance may vary slightly by product and region.

Sources: Manufacturer instructions; Mayo Clinic; CDC clinical guidance.

Side effects and adverse events

Common, typically transient side effects include:

Vaginal symptoms: increased vaginal discharge, irritation, or discomfort. Some users report spotting or breakthrough bleeding, especially during the first few cycles (Mayo Clinic; Cleveland Clinic).
Systemic symptoms: headache, nausea, breast tenderness, mood changes, and intermittent changes in libido. Weight changes are reported by some users, though robust evidence for significant weight gain caused by combined hormonal methods in general is limited (Mayo Clinic; NIH resources).

Serious but uncommon risks related to combined hormonal contraceptive use include:

Venous thromboembolism (VTE): Combined estrogen–progestin products are associated with a small increased risk of deep vein thrombosis and pulmonary embolism, especially in users with additional risk factors (e.g., smoking, age >35, obesity, personal or strong family history of VTE, known thrombophilia) (ACOG; CDC).
Arterial events: Increased risk of myocardial infarction or ischemic stroke in users with multiple risk factors, particularly cigarette smokers aged 35 years and older and people with uncontrolled hypertension or migraines with aura (ACOG; CDC).
Liver dysfunction: Rarely, serious liver disorders or benign hepatic tumors have been reported with hormonal contraceptive use; ring users with unexplained persistent abnormal liver tests should be evaluated (product labeling; ACOG).

If severe symptoms such as sudden leg pain/swelling, sudden chest pain or shortness of breath, severe or sudden headache, vision changes, slurred speech, or jaw/arm/leg weakness occur, seek immediate medical care because these may represent thrombotic or cerebrovascular events.

Sources: ACOG; CDC; Mayo Clinic.

Drug interactions and factors that reduce efficacy

Certain medications and herbal supplements can reduce the contraceptive effectiveness of combined hormonal rings by inducing hepatic enzymes that increase hormone metabolism. Examples include:

Anticonvulsants: carbamazepine, phenytoin, phenobarbital, topiramate (at higher doses).
Antibiotic rifampin and rifabutin (strong inducers).
Some HIV medications (certain protease inhibitors and non-nucleoside reverse transcriptase inhibitors) — interactions vary by agent.
The herbal product St. John’s wort (Hypericum perforatum).

If you require a medication that induces hepatic enzymes, discuss alternative contraception or additional precautions with your clinician. Some interactions are clinically important and require a different contraceptive method (CDC; NIH drug information).

Sources: CDC; National Institutes of Health (MedlinePlus/Drug Information).

Impact on menstruation, fertility after stopping, and breastfeeding

Menstrual effects: Many users experience lighter and more regular withdrawal bleeding while using the ring. Some users have amenorrhea (absence of bleeding) or unpredictable spotting, especially during the first months of use (Mayo Clinic).

Return to fertility: Fertility typically returns rapidly after discontinuation. Ovulation may occur as soon as 1–2 cycles after stopping the ring; most users who desire pregnancy conceive within a few months, depending on baseline fertility (ACOG; Mayo Clinic).

Breastfeeding: Combined estrogen–progestin methods are generally not recommended as first‑line contraception for breastfeeding people in the early postpartum period (first 6 weeks) because estrogen can reduce milk supply in some individuals. Progestin-only methods are preferred initially for lactating persons who need contraception. Clinicians should individualize recommendations based on timing postpartum, breastfeeding status, and risk factors (ACOG; CDC).

Sources: ACOG; CDC; Mayo Clinic.

Advantages and disadvantages

Advantages

Convenience: Monthly or annual routine rather than daily dosing improves adherence for many users.
Privacy: No external visible device or daily pill necessary.
Rapid return to fertility after discontinuation.
Comparable side effect profile to combined oral contraceptives with generally low systemic hormone levels (Mayo Clinic; Cleveland Clinic).
Reusable option (Annovera) reduces the need for monthly pharmacy visits.

Disadvantages

Does not protect against sexually transmitted infections (STIs); barrier methods are required for STI prevention.
Requires correct timing and reinsertion to maintain full effectiveness; expulsions or delayed insertion reduce protection.
Not suitable for persons with contraindications to estrogen-containing contraception.
Possible vaginal irritation or increased discharge in some users.
Some drug interactions can reduce effectiveness (CDC; Mayo Clinic).

Sources: Mayo Clinic; Cleveland Clinic; CDC.

Comparison with other contraceptive methods

Vs. combined oral contraceptives: Ring eliminates the need for daily adherence and may provide steadier hormone release; effectiveness is similar when both are used correctly, but typical-use efficacy depends on user behavior (Mayo Clinic).

Vs. transdermal patch: Similar hormone class and comparable effectiveness; patch is external and visible, whereas the ring is internal and not visible.

Vs. long-acting reversible contraception (IUDs, implants): IUDs and implants are more effective in typical use and do not require user action each month. Rings are user-controlled and reversible with immediate return to fertility; LARC methods require a trained clinician for insertion and removal (ACOG).

Vs. progestin-only methods: Progestin-only pills, implants, and some intrauterine systems avoid the estrogen-associated risks and may be preferred for those who are breastfeeding or have contraindications to estrogen. However, progestin-only pills require strict dosing times, and implants/IUDs are procedural (ACOG; CDC).

Sources: ACOG; CDC; Mayo Clinic.

When to seek medical attention

Seek prompt medical evaluation if you experience:

Signs of possible thromboembolism: sudden leg pain/swelling, chest pain, shortness of breath.
Neurological symptoms: severe or sudden headache, vision changes, speech disturbances, weakness or numbness.
Symptoms suggestive of severe liver dysfunction: jaundice (yellowing of skin or eyes), dark urine, severe abdominal pain.
Persistent or severe vaginal pain, bleeding, or malodorous discharge that may indicate infection.
Unexpected or prolonged absence of withdrawal bleeding after discontinuation when pregnancy needs to be ruled out.

Routine follow-up with a clinician is recommended to review tolerance, address side effects, and reassess risk factors (ACOG; Mayo Clinic).

Sources: ACOG; Mayo Clinic.

Practical questions clinicians and patients commonly ask

Can I leave the ring in during bathing or swimming?
Yes. Routine bathing, showering, swimming, or exercise does not affect the ring’s function (Mayo Clinic).

Is the ring likely to be felt by the person using it or their partner?
Most users do not feel the ring once it is positioned comfortably. If there is discomfort, the ring can be repositioned. If a partner feels the ring and this is bothersome, a clinician can discuss options (Mayo Clinic; Cleveland Clinic).

Can I use tampons or menstrual cups with the ring?
Tampons may be used; they generally do not interfere with the ring. If using a menstrual cup, care should be taken during insertion and removal because the ring can occasionally be displaced; follow product manufacturer guidance and discuss with your clinician (product labeling; Mayo Clinic).

What if I vomit or have diarrhea?
Because the ring does not rely on gastrointestinal absorption, vomiting and diarrhea do not affect its effectiveness in the same way they can affect oral pills. However, if the ring is expelled during these events and remains out for more than a short interval, follow the expulsion guidance described above (Mayo Clinic).

Sources: Mayo Clinic; product labeling.

Access, cost, and prescription considerations

The vaginal ring is a prescription device in most countries. Access may be through primary care clinicians, family planning clinics, gynecologists, or telemedicine services depending on local practice. Insurance coverage and out-of-pocket costs vary by country and plan. Some programs and clinics may provide the ring at low or no cost for eligible patients. Discuss access options with a clinician or local family planning services.

Clinicians typically perform a brief medical history and blood pressure check before prescribing combined hormonal contraception to screen for contraindications and assess risk factors in accordance with standardized guidelines (CDC; ACOG).

Sources: CDC; ACOG.

Summary

The vaginal contraceptive ring is a safe, effective, reversible method of combined hormonal contraception for many people. It offers a convenient alternative to daily pills by providing sustained hormone release with monthly (or yearly, for reusable systems) use. Like all combined hormonal methods, rings carry small but important risks—especially for individuals with certain cardiovascular, thrombotic, or cancer‑related contraindications—and require appropriate medical evaluation before initiation. Patients should receive counseling on correct use, what to do for expulsions or missed rings, potential side effects, and interactions with other medications. For individualized guidance, risks, and alternatives, consult a clinician or family planning provider and refer to authoritative clinical resources such as ACOG, CDC, NIH/MedlinePlus, Mayo Clinic, and Cleveland Clinic.

Authoritative resources and clinical references

American College of Obstetricians and Gynecologists (ACOG) — clinical guidance on hormonal contraception and patient counseling.
Centers for Disease Control and Prevention (CDC) — U.S. Medical Eligibility Criteria (MEC) for Contraceptive Use and clinical guidance.
Mayo Clinic — patient information for etonogestrel/ethinyl estradiol vaginal ring.
Cleveland Clinic — patient information on vaginal ring contraception.
U.S. Food and Drug Administration (FDA) — product labeling and prescribing information (e.g., Annovera).

(For detailed, up-to-date guidance consult the referenced organizations’ websites and your prescribing clinician.)